niacinamide has been researched along with Bladder Cancer in 44 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule." | 9.08 | Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. ( Cladd, H; Goodchild, K; Hoskin, PJ; Phillips, H; Powell, ME; Rojas, A; Saunders, MI; Stratford, MR, 1997) |
| "Using a panel of human bladder cancer cell lines (RT4, T24, J82), we characterized systematically the effects of sorafenib on intracellular signalling, migration, proliferation and apoptosis." | 7.76 | Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. ( Fischer, JW; Grandoch, M; Rose, A; Rosenkranz, A; Rübben, H; vom Dorp, F; Weber, AA, 2010) |
| "In a comparative study of tryptophan metabolism and urinary excretion of nucleic acid derivatives (including beta-aminoisobutyric acid, 7-methylguanine, pseudouridine, and urate) in 12 male bladder cancer patients, the excretion of pseudouridine and 7-methylguanine decreased significantly after an oral dose of 2 g L-tryptophan." | 7.65 | Effect of tryptophan and nicotinamide loads on urinary excretion of RNA metabolites by bladder cancer patients. ( Brown, RR; Nielsen, HR; Wolf, H, 1977) |
| "The incidence of bladder cancer increases with age, and elderly patients with muscle invasive bladder cancer (MIBC) are significantly undertreated." | 5.62 | Concurrent carbogen and nicotinamide with radiation therapy in muscle invasive bladder cancer: A report on feasibility in the Australian setting. ( Anzela, A; Azzopardi, M; Barrett, S; Buddle, N; Hooshmand, R; Knesl, M; Min, M; Notman, A; Vignarajah, DD; Wilson, J; Woolls, H, 2021) |
| "The effect of the combined treatment on bladder cancer cells was verified in T24 cells." | 5.46 | Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells. ( Cao, JY; Han, X; Li, HS; Yin, HS; Yu, XQ, 2017) |
| "A 14-miRNA hypoxia signature can be used with an mRNA hypoxia signature to identify bladder cancer patients benefitting most from having carbogen and nicotinamide with radiotherapy." | 5.41 | A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer. ( Aragaki, K; Choudhury, A; Dyrskjøt, L; Hoskin, PJ; Irlam-Jones, JJ; Khan, MT; Lane, B; McConkey, DJ; Pereira, RR; Valentine, HR; West, CML, 2021) |
| "Urothelial bladder cancer is the ninth most common cancer." | 5.39 | Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer. ( Fischer, JW; Freudenberger, T; Kretschmer, I; Nagy, N; Niedworok, C; Reis, H; Röck, K; Rübben, H; Szarvas, T; Vom Dorp, F, 2013) |
| "Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer." | 5.17 | Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. ( Agrawal, S; Choudhury, A; Denley, H; Eustace, A; Harris, AL; Hoskin, PJ; Irlam, JJ; Ord, JJ; Rojas, AM; Ryder, D; Taylor, J; West, CM, 2013) |
| "Samples were available from 157 T2-T4 laryngeal cancer and 185 T1-T4a bladder cancer patients enrolled on the accelerated radiotherapy with carbogen and nicotinamide (ARCON) and bladder carbogen nicotinamide (BCON) phase III randomized trials of radiotherapy alone or with carbogen and nicotinamide (CON) respectively." | 5.17 | A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. ( Betts, GN; Buffa, FM; Denley, H; Eustace, A; Harris, AL; Homer, JJ; Hoskin, PJ; Irlam, JJ; Kaanders, JH; Mani, N; Miller, CJ; Rojas, AM; Span, PN; Taylor, J; West, CM, 2013) |
| "Carbogen and nicotinamide have been evaluated in a phase II study as hypoxia-modifying agents during radical radiotherapy for bladder cancer using a standard daily 20-fraction schedule." | 5.08 | Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. ( Cladd, H; Goodchild, K; Hoskin, PJ; Phillips, H; Powell, ME; Rojas, A; Saunders, MI; Stratford, MR, 1997) |
| "Using a panel of human bladder cancer cell lines (RT4, T24, J82), we characterized systematically the effects of sorafenib on intracellular signalling, migration, proliferation and apoptosis." | 3.76 | Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. ( Fischer, JW; Grandoch, M; Rose, A; Rosenkranz, A; Rübben, H; vom Dorp, F; Weber, AA, 2010) |
| "In a comparative study of tryptophan metabolism and urinary excretion of nucleic acid derivatives (including beta-aminoisobutyric acid, 7-methylguanine, pseudouridine, and urate) in 12 male bladder cancer patients, the excretion of pseudouridine and 7-methylguanine decreased significantly after an oral dose of 2 g L-tryptophan." | 3.65 | Effect of tryptophan and nicotinamide loads on urinary excretion of RNA metabolites by bladder cancer patients. ( Brown, RR; Nielsen, HR; Wolf, H, 1977) |
| "Many muscle-invasive bladder cancers are hypoxic, which limits the efficacy of radiation therapy." | 3.01 | Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). ( Choudhury, A; Hoskin, PJ; Irlam, J; Lane, B; Mistry, H; Song, YP; Valentine, H; West, C; Yang, L, 2021) |
| "Sorafenib was combined with gemcitabine and cisplatin chemotherapy (SGC) in an open-label, single-arm, phase 2 trial (NCT01222676)." | 2.87 | Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. ( Biasoni, D; Busico, A; Calareso, G; Catanzaro, M; Colecchia, M; Giannatempo, P; Lo Vullo, S; Mariani, L; Necchi, A; Nicolai, N; Pennati, M; Perrone, F; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Togliardi, E; Torelli, T; Zaffaroni, N, 2018) |
| " However, some studies have been stopped owing to the development of severe adverse events." | 2.80 | Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer. ( Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H, 2015) |
| "In most cases, death from bladder cancer results from metastatic disease." | 2.45 | Targeting angiogenesis in bladder cancer. ( Elfiky, AA; Rosenberg, JE, 2009) |
| "The incidence of bladder cancer increases with age, and elderly patients with muscle invasive bladder cancer (MIBC) are significantly undertreated." | 1.62 | Concurrent carbogen and nicotinamide with radiation therapy in muscle invasive bladder cancer: A report on feasibility in the Australian setting. ( Anzela, A; Azzopardi, M; Barrett, S; Buddle, N; Hooshmand, R; Knesl, M; Min, M; Notman, A; Vignarajah, DD; Wilson, J; Woolls, H, 2021) |
| "The effect of the combined treatment on bladder cancer cells was verified in T24 cells." | 1.46 | Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells. ( Cao, JY; Han, X; Li, HS; Yin, HS; Yu, XQ, 2017) |
| "Urothelial bladder cancer is the ninth most common cancer." | 1.39 | Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer. ( Fischer, JW; Freudenberger, T; Kretschmer, I; Nagy, N; Niedworok, C; Reis, H; Röck, K; Rübben, H; Szarvas, T; Vom Dorp, F, 2013) |
| "Urinary bladder cancer is often a result of exposure to chemical carcinogens such as cigarette smoking." | 1.37 | Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model. ( Bae, SC; Kim, J; Kim, SK; Kim, WJ; Lee, OJ; Yun, SJ, 2011) |
| "The NQO activity of ovarian and bladder tumors was determined and the effect of NQO polymorphisms on NQO activity was investigated." | 1.34 | NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. ( Boddy, AV; Edmondson, RJ; Jamieson, D; Knox, R; Leung, HY; Margetts, JP; Pridgeon, S; Wilson, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (27.27) | 18.7374 |
| 1990's | 4 (9.09) | 18.2507 |
| 2000's | 10 (22.73) | 29.6817 |
| 2010's | 15 (34.09) | 24.3611 |
| 2020's | 3 (6.82) | 2.80 |
| Authors | Studies |
|---|---|
| Song, YP | 1 |
| Mistry, H | 1 |
| Irlam, J | 1 |
| Valentine, H | 1 |
| Yang, L | 2 |
| Lane, B | 2 |
| West, C | 1 |
| Choudhury, A | 4 |
| Hoskin, PJ | 10 |
| Khan, MT | 1 |
| Irlam-Jones, JJ | 1 |
| Pereira, RR | 1 |
| Valentine, HR | 1 |
| Aragaki, K | 1 |
| Dyrskjøt, L | 1 |
| McConkey, DJ | 1 |
| West, CML | 2 |
| Anzela, A | 1 |
| Min, M | 1 |
| Knesl, M | 1 |
| Buddle, N | 1 |
| Azzopardi, M | 1 |
| Hooshmand, R | 1 |
| Barrett, S | 1 |
| Notman, A | 1 |
| Woolls, H | 1 |
| Wilson, J | 1 |
| Vignarajah, DD | 1 |
| Taylor, J | 3 |
| Eustace, A | 3 |
| Irlam, JJ | 3 |
| Denley, H | 3 |
| Alsner, J | 1 |
| Buffa, FM | 2 |
| Harris, AL | 3 |
| Cao, JY | 1 |
| Yin, HS | 1 |
| Li, HS | 1 |
| Yu, XQ | 1 |
| Han, X | 1 |
| Necchi, A | 1 |
| Lo Vullo, S | 1 |
| Raggi, D | 1 |
| Perrone, F | 1 |
| Giannatempo, P | 1 |
| Calareso, G | 1 |
| Togliardi, E | 1 |
| Nicolai, N | 1 |
| Piva, L | 1 |
| Biasoni, D | 1 |
| Catanzaro, M | 1 |
| Torelli, T | 1 |
| Stagni, S | 1 |
| Colecchia, M | 1 |
| Busico, A | 1 |
| Pennati, M | 1 |
| Zaffaroni, N | 1 |
| Mariani, L | 1 |
| Salvioni, R | 1 |
| Mierzejewska, P | 1 |
| Gawlik-Jakubczak, T | 1 |
| Jablonska, P | 1 |
| Czajkowski, M | 1 |
| Kutryb-Zajac, B | 1 |
| Smolenski, RT | 1 |
| Matuszewski, M | 1 |
| Slominska, EM | 1 |
| Ho, JN | 1 |
| Byun, SS | 1 |
| Lee, SE | 1 |
| Youn, JI | 1 |
| Lee, S | 1 |
| Agrawal, S | 1 |
| Ryder, D | 1 |
| Ord, JJ | 1 |
| Rojas, AM | 5 |
| West, CM | 2 |
| Mani, N | 1 |
| Span, PN | 1 |
| Betts, GN | 1 |
| Miller, CJ | 1 |
| Homer, JJ | 1 |
| Kaanders, JH | 2 |
| Niedworok, C | 1 |
| Röck, K | 1 |
| Kretschmer, I | 1 |
| Freudenberger, T | 1 |
| Nagy, N | 1 |
| Szarvas, T | 1 |
| Vom Dorp, F | 3 |
| Reis, H | 1 |
| Rübben, H | 3 |
| Fischer, JW | 2 |
| Knievel, J | 1 |
| Schulz, WA | 1 |
| Greife, A | 1 |
| Hader, C | 1 |
| Lübke, T | 1 |
| Schmitz, I | 1 |
| Albers, P | 1 |
| Niegisch, G | 1 |
| Miyata, Y | 1 |
| Asai, A | 1 |
| Mitsunari, K | 1 |
| Matsuo, T | 1 |
| Ohba, K | 1 |
| Sakai, H | 1 |
| Börgermann, C | 1 |
| Rose, A | 2 |
| Becker, M | 1 |
| Saunders, MI | 5 |
| Bentzen, SM | 2 |
| Motohashi, KJ | 1 |
| Hoskin, P | 1 |
| Rojas, A | 2 |
| Saunders, M | 1 |
| Elfiky, AA | 1 |
| Rosenberg, JE | 1 |
| Dreicer, R | 1 |
| Li, H | 1 |
| Stein, M | 1 |
| DiPaola, R | 1 |
| Eleff, M | 1 |
| Roth, BJ | 1 |
| Wilding, G | 1 |
| Grandoch, M | 1 |
| Rosenkranz, A | 1 |
| Weber, AA | 1 |
| Pinto, A | 1 |
| Redondo, A | 1 |
| Zamora, P | 1 |
| Castelo, B | 1 |
| Espinosa, E | 1 |
| Kim, WJ | 2 |
| Lee, JW | 1 |
| Quan, C | 1 |
| Youn, HJ | 1 |
| Kim, HM | 1 |
| Bae, SC | 2 |
| Kim, SK | 1 |
| Yun, SJ | 1 |
| Kim, J | 1 |
| Lee, OJ | 1 |
| Bussink, J | 1 |
| van der Kogel, AJ | 1 |
| QUAGLIARIELLO, E | 2 |
| TANCREDI, F | 2 |
| FEDELE, L | 2 |
| SACCONE, C | 2 |
| KERR, WK | 1 |
| BARKIN, M | 1 |
| LEVERS, PE | 1 |
| WOO, SK | 1 |
| MENCZYK, Z | 1 |
| Phillips, H | 2 |
| Jamieson, D | 1 |
| Wilson, K | 1 |
| Pridgeon, S | 1 |
| Margetts, JP | 1 |
| Edmondson, RJ | 1 |
| Leung, HY | 1 |
| Knox, R | 1 |
| Boddy, AV | 1 |
| Silay, MS | 1 |
| Miroglu, C | 1 |
| Pamukcu, AM | 1 |
| Milli, U | 1 |
| Bryan, GT | 1 |
| Cladd, H | 1 |
| Powell, ME | 1 |
| Goodchild, K | 1 |
| Stratford, MR | 1 |
| Denekamp, J | 1 |
| Fowler, JF | 1 |
| Dische, S | 1 |
| Iinuma, S | 1 |
| Schomacker, KT | 1 |
| Wagnieres, G | 1 |
| Rajadhyaksha, M | 1 |
| Bamberg, M | 1 |
| Momma, T | 1 |
| Hasan, T | 1 |
| Droller, MJ | 1 |
| Nielsen, HR | 1 |
| Wolf, H | 2 |
| Brown, RR | 5 |
| Schoental, R | 1 |
| Leklem, JE | 2 |
| Woodford, J | 1 |
| Crawford, MA | 1 |
| Hansen, IL | 1 |
| Lopez, A | 1 |
| Rose, DP | 1 |
| Price, JM | 2 |
| Burney, SW | 1 |
| Friedell, GH | 1 |
| Hankes, LV | 1 |
| Schmaeler, M | 1 |
| Schievelbein, H | 1 |
| Kuntze, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder[NCT01222676] | Phase 2 | 45 participants (Anticipated) | Interventional | 2010-10-31 | Recruiting | ||
| A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer[NCT00033436] | Phase 3 | 330 participants (Anticipated) | Interventional | 2000-10-31 | Completed | ||
| Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib[NCT02416739] | Phase 2/Phase 3 | 110 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for niacinamide and Bladder Cancer
| Article | Year |
|---|---|
Targeting angiogenesis in bladder cancer.
Topics: Angiogenesis Inhibitors; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2009 |
Angiogenesis as a therapeutic target in urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzene | 2010 |
ARCON: a novel biology-based approach in radiotherapy.
Topics: Animals; Carbon Dioxide; Carcinoma; Cell Cycle; Cell Hypoxia; Clinical Trials as Topic; Dose Fractio | 2002 |
ARCON--current status: summary of a workshop on preclinical and clinical studies.
Topics: Animals; Carbon Dioxide; Cell Division; Cell Hypoxia; Head and Neck Neoplasms; Humans; Neoplasm Recu | 1997 |
13 trials available for niacinamide and Bladder Cancer
| Article | Year |
|---|---|
Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbon Dioxide; Confidence Intervals; Disease-Fre | 2021 |
A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.
Topics: Biomarkers, Tumor; Carbon Dioxide; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2021 |
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Female; | 2018 |
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Carbonic Anhydrase IV; Cell Hypoxia; Female; Glucose Transp | 2013 |
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Topics: Carbon Dioxide; Cell Hypoxia; Female; Gene Expression Regulation, Neoplastic; Humans; Laryngeal Neop | 2013 |
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxy | 2015 |
Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Transitional Cell; Dose Fractionation, Radiation | 2009 |
Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma in Situ; Cystectomy; Dose Fractionation, R | 2009 |
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Transitional Cell; Disease-Free Surviv | 2009 |
Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
Topics: Aged; Aged, 80 and over; Carbon Dioxide; Cystectomy; Female; Humans; Male; Middle Aged; Neoplasm Sta | 2010 |
Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Squamous Cell; Carcinoma, Transitional Ce | 2005 |
Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
Topics: Aged; Carbon Dioxide; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Male; Middl | 1997 |
Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
Topics: Adult; Aged; Carbon Dioxide; Humans; Hyperbaric Oxygenation; Middle Aged; Misonidazole; Niacinamide; | 1999 |
27 other studies available for niacinamide and Bladder Cancer
| Article | Year |
|---|---|
Concurrent carbogen and nicotinamide with radiation therapy in muscle invasive bladder cancer: A report on feasibility in the Australian setting.
Topics: Aged; Australia; Carbon Dioxide; Feasibility Studies; Humans; Muscles; Neoplasm Recurrence, Local; N | 2021 |
A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients.
Topics: Aged; Carbon Dioxide; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Gene E | 2017 |
Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergis | 2017 |
Nicotinamide metabolism alterations in bladder cancer: Preliminary studies.
Topics: Aged; Biomarkers, Tumor; Case-Control Studies; Female; Humans; Male; Middle Aged; Niacinamide; Pyrid | 2018 |
Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin‑resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cis | 2019 |
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
Topics: Animals; Biglycan; Gene Expression Regulation, Neoplastic; Humans; Indoles; Leucine; Male; Mice; Mic | 2013 |
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; MAP Kinase Si | 2014 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Move | 2010 |
Nicotinamide inhibits growth of carcinogen induced mouse bladder tumor and human bladder tumor xenograft through up-regulation of RUNX3 and p300.
Topics: Animals; Core Binding Factor Alpha 3 Subunit; Disease Models, Animal; E1A-Associated p300 Protein; H | 2011 |
Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model.
Topics: Animals; Butylhydroxybutylnitrosamine; Disease Models, Animal; Female; Gene Expression Profiling; Ge | 2011 |
Tryptophan-nicotinic acid metabolism in patients with tumours of the bladder. Changes in the excretory products after treatment with nicotinamide and vitamin B6.
Topics: Humans; Neoplasms; Niacin; Niacinamide; Nicotinic Acids; Tryptophan; Urinary Bladder Neoplasms; Vita | 1961 |
[Studies on the metabolic conversion of tryptophan into nicotinic acid in individuals with tumors of the bladder. Modifications in the urinary excretory picture after the administration of nicotinamide and vitamin B6].
Topics: Humans; Neoplasms; Niacin; Niacinamide; Nicotinic Acids; Tryptophan; Urinary Bladder Neoplasms; Vita | 1960 |
THE EFFECT OF CIGARETTE SMOKING ON BLADDER CARCINOGENS IN MAN.
Topics: Amino Acids; Carcinogens; Humans; Male; Metabolism; Neoplasms; Niacin; Niacinamide; Nicotiana; Smoki | 1965 |
NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Topics: Female; Humans; NAD(P)H Dehydrogenase (Quinone); Niacinamide; Ovarian Neoplasms; Polymorphism, Restr | 2007 |
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacina | 2007 |
Protective effect of nicotinamide on bracken fern induced carcinogenicity in rats.
Topics: Animals; Body Weight; Female; Intestinal Neoplasms; Male; NAD; Neoplasms, Experimental; Niacinamide; | 1981 |
In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model.
Topics: Aminolevulinic Acid; Animals; Dermatitis, Phototoxic; Disease Models, Animal; Female; Light; Microsc | 1999 |
Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide.
Topics: Carbon Dioxide; Humans; Hyperbaric Oxygenation; Misonidazole; Niacinamide; Oxygen; Radiation-Sensiti | 2000 |
Effect of tryptophan and nicotinamide loads on urinary excretion of RNA metabolites by bladder cancer patients.
Topics: Aminoisobutyric Acids; Guanine; Humans; Male; Niacinamide; Pseudouridine; RNA, Neoplasm; Tryptophan; | 1977 |
Pancreatic islet-cell and other tumors in rats given heliotrine, a monoester pyrrolizidine alkaloid, and nicotinamide.
Topics: Adenoma; Adenoma, Islet Cell; Animals; Carcinoma, Hepatocellular; Hyperplasia; Liver Neoplasms; Male | 1975 |
Comparative tryptophan metabolism in cats and rats: differences in adaptation of tryptophan oxygenase and in vivo metabolism of tryptophan, kynurenine and hydroxykynurenine.
Topics: Amino Acids; Aminohippuric Acids; Animals; Cats; Enzyme Induction; Glucuronates; Hydrocortisone; Ind | 1969 |
The excretion of 3-hydroxyanthranilic and quinolinic acid in Uganda Africans.
Topics: Adult; Analysis of Variance; Creatinine; Diet; Edible Grain; Female; Fruit; Humans; Kynurenic Acid; | 1969 |
Tryptophan metabolism as affected by anovulatory agents.
Topics: Aminohippuric Acids; Chlorotrianisene; Diethylstilbestrol; Estrogens; Female; Humans; Isoniazid; Kyn | 1969 |
Lack of effect of smoking on the excretion of tryptophan metabolites by man.
Topics: Adult; Aminohippuric Acids; Female; Glucuronates; Humans; Kynurenic Acid; Kynurenine; Male; Middle A | 1970 |
Tryptophan metabolism in the cat: a study with carbon-14-labeled compounds.
Topics: Aminohippuric Acids; Animals; Carbon Dioxide; Carbon Isotopes; Cat Diseases; Cats; Kynurenine; Male; | 1971 |
[Proceedings: Tryptophan metabolism, bladder carcinoma and smoking habits].
Topics: 3-Hydroxyanthranilic Acid; Carcinoma; Humans; Kynurenine; Niacinamide; Smoking; Tryptophan; Urinary | 1972 |